Laure Brulhart

B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents

Axel Finckh, Adrian Ciurea, Laure Brulhart et al. · Arthritis & Rheumatism · 2007 · 210 citations

Life Sciences, Immunology, Internal Medicine +14

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Axel Finckh, Adrian Ciurea, Laure Brulhart et al. · Annals of the Rheumatic Diseases · 2009 · 171 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland

Axel Finckh, Christoph Tellenbach, Lisa Herzog et al. · RMD Open · 2020 · 70 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: Results of an observational cohort study

Pascal Zufferey, Burkhard Möller, Laure Brulhart et al. · Joint Bone Spine · 2014 · 50 citations

Medicine, Immunology, Autoimmunity +16

Ultrasound evaluation of synovitis in RA: Correlation with clinical disease activity and sensitivity to change in an observational cohort study

Pascal Zufferey, Laure Brulhart, Giorgio Tamborrini et al. · Joint Bone Spine · 2013 · 38 citations

Medicine, Clinical Sciences, Internal Medicine +14